We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain BXP Stock in Your Portfolio Now
Read MoreHide Full Article
BXP, Inc. (BXP - Free Report) boasts a portfolio of Class A office assets in a few select markets of the United States. Healthy tenant demand for premier office assets and a diverse tenant base ensures stable revenues. A strong balance sheet and efforts to convert office buildings to laboratory spaces amid strong demand for life-science assets bode well for growth. BXP’s strategic capital allocation boosts portfolio expansion.
However, the flexible working environment is affecting the demand for office properties. A huge development outlay adds to the company's concerns.
Over the past six months, shares of this office REIT, carrying a Zacks Rank #3 (Hold), have rallied 33.7%, outperforming the industry's 14% growth.
Image Source: Zacks Investment Research
What’s Aiding BXP?
BXP's portfolio of premier office assets, concentrated in a few select high-rent, high barrier-to-entry geographic markets and a solid tenant base, enables it to generate stable rental revenues. As of Sept. 30, 2024, the weighted average remaining lease term for its 20 largest clients, based on leased square footage, was 9.5 years. Its long-term leases with tenants having a solid credit profile assure stable cash flows.
The return-to-office policies implemented by many companies, coupled with a relatively low unemployment rate and consistent job growth, are likely to drive the demand for BXP's strategically located, high-quality office properties. A total of 3.3 million square feet of leasing was executed in the first three quarters of 2024, representing a 25% increase compared to the same period in 2023. We estimate lease revenues to witness a year-over-year increase of 3.6% in 2024.
Amid strong demand from life-science tenants, the company is converting numerous straight office buildings to laboratory/life-science spaces in its suburban portfolio. As of Sept. 30, 2024, BXP had four life-science projects under development, encompassing 1.2 million RSF with an estimated total investment of $903.1 million (BXP’s share) and 70% pre-leased.
BXP has been focusing on the successful execution of its capital reallocation strategy. From the beginning of 2010 through the end of the third quarter of 2024, BXP carried out acquisitions worth $7.5 billion at its share. It also disposed of properties for an aggregate amount of $8.2 billion at its share during this period. Such moves highlight the company’s prudent capital management practices and relieve pressure on its balance sheet.
BXP has a healthy balance sheet position with ample liquidity. As of Sept. 30, 2024, the company had $3.0 billion of liquidity. Its share of net debt to EBITDAre (annualized) was 7.6X, while the fixed charge coverage ratio was 2.4 times as of the same date. BXP also enjoys unsecured senior debt ratings of BBB from S&P Global Ratings and Baa2 from Moody’s, rendering it favorable access to the debt market.
What’s Hurting BXP?
The U.S. office real estate market continues to witness slow demand due to the continuation of a flexible working environment, which has diminished office space utilization. Although property tours and leases under negotiation continue to take place, there is less urgency from clients to make new commitments.
For the third quarter of 2024, BXP’s in-service properties’ occupancy fell 10 basis points sequentially to 87.0%. We do not foresee considerable improvement in the near term and expect the company to maintain an occupancy rate of 87.3% in 2024.
BXP has nine properties under its development and redevelopment pipeline, with its share of estimated total investment aggregating around $2.05 billion as of Sept. 30, 2024. Although a huge development pipeline is encouraging for long-term growth, it exposes the company to the risk of rising construction costs and lease-up concerns.
The Zacks Consensus Estimate for Welltower’s 2024 FFO per share has been raised marginally northward over the past month to $4.26.
The Zacks Consensus Estimate for Cousins Properties’ current-year FFO per share has been revised marginally upward over the past month to $2.68.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Here's Why You Should Retain BXP Stock in Your Portfolio Now
BXP, Inc. (BXP - Free Report) boasts a portfolio of Class A office assets in a few select markets of the United States. Healthy tenant demand for premier office assets and a diverse tenant base ensures stable revenues. A strong balance sheet and efforts to convert office buildings to laboratory spaces amid strong demand for life-science assets bode well for growth. BXP’s strategic capital allocation boosts portfolio expansion.
However, the flexible working environment is affecting the demand for office properties. A huge development outlay adds to the company's concerns.
Over the past six months, shares of this office REIT, carrying a Zacks Rank #3 (Hold), have rallied 33.7%, outperforming the industry's 14% growth.
Image Source: Zacks Investment Research
What’s Aiding BXP?
BXP's portfolio of premier office assets, concentrated in a few select high-rent, high barrier-to-entry geographic markets and a solid tenant base, enables it to generate stable rental revenues. As of Sept. 30, 2024, the weighted average remaining lease term for its 20 largest clients, based on leased square footage, was 9.5 years. Its long-term leases with tenants having a solid credit profile assure stable cash flows.
The return-to-office policies implemented by many companies, coupled with a relatively low unemployment rate and consistent job growth, are likely to drive the demand for BXP's strategically located, high-quality office properties. A total of 3.3 million square feet of leasing was executed in the first three quarters of 2024, representing a 25% increase compared to the same period in 2023. We estimate lease revenues to witness a year-over-year increase of 3.6% in 2024.
Amid strong demand from life-science tenants, the company is converting numerous straight office buildings to laboratory/life-science spaces in its suburban portfolio. As of Sept. 30, 2024, BXP had four life-science projects under development, encompassing 1.2 million RSF with an estimated total investment of $903.1 million (BXP’s share) and 70% pre-leased.
BXP has been focusing on the successful execution of its capital reallocation strategy. From the beginning of 2010 through the end of the third quarter of 2024, BXP carried out acquisitions worth $7.5 billion at its share. It also disposed of properties for an aggregate amount of $8.2 billion at its share during this period. Such moves highlight the company’s prudent capital management practices and relieve pressure on its balance sheet.
BXP has a healthy balance sheet position with ample liquidity. As of Sept. 30, 2024, the company had $3.0 billion of liquidity. Its share of net debt to EBITDAre (annualized) was 7.6X, while the fixed charge coverage ratio was 2.4 times as of the same date. BXP also enjoys unsecured senior debt ratings of BBB from S&P Global Ratings and Baa2 from Moody’s, rendering it favorable access to the debt market.
What’s Hurting BXP?
The U.S. office real estate market continues to witness slow demand due to the continuation of a flexible working environment, which has diminished office space utilization. Although property tours and leases under negotiation continue to take place, there is less urgency from clients to make new commitments.
For the third quarter of 2024, BXP’s in-service properties’ occupancy fell 10 basis points sequentially to 87.0%. We do not foresee considerable improvement in the near term and expect the company to maintain an occupancy rate of 87.3% in 2024.
BXP has nine properties under its development and redevelopment pipeline, with its share of estimated total investment aggregating around $2.05 billion as of Sept. 30, 2024. Although a huge development pipeline is encouraging for long-term growth, it exposes the company to the risk of rising construction costs and lease-up concerns.
Stocks to Consider
Some better-ranked stocks from the broader REIT sector are Welltower (WELL - Free Report) and Cousins Properties (CUZ - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Welltower’s 2024 FFO per share has been raised marginally northward over the past month to $4.26.
The Zacks Consensus Estimate for Cousins Properties’ current-year FFO per share has been revised marginally upward over the past month to $2.68.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.